Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan(TM) Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

These nondilutive funds support development, testing and IND submission of the Company's pediatric esophageal implant candidate HOLLISTON, Mass., Nov. 6­­­, 2018 -- (Healthcare Sales & Marketing Network) -- Biostage, Inc. (OTCQB: BSTG), a b... Regenerative Medicine Biostage, Cellspan, Esophageal Implant, Cellframe, esophageal atresia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news